$NDRA
ENDRA Life Sciences Inc. Stock $ndra

$ndra Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000165495423003044 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.548M	$1.650M	$6.603M
YoY Change	-5.74%	0.08%	9.77%
% of Gross Profit
Research & Development	$1.391M	$1.663M	$6.554M
YoY Change	14.7%	16.9%	19.55%
% of Gross Profit
Depreciation & Amortization	$34.52K	$32.13K	$96.66K
YoY Change	81.3%	51.13%	-16.84%
% of Gross Profit
Operating Expenses	$2.939M	$3.313M	$13.16M
YoY Change	2.94%	7.87%	14.43%
Operating Profit	-$2.939M		-$13.16M
YoY Change	2.94%		14.43%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.418K	$23.79K	-$21.53K
YoY Change	16.54%	-171.89%	-108.06%
Pretax Income	-$2.943M	-$3.290M	-$13.18M
YoY Change	2.96%	5.96%	17.34%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.943M	-$3.290M	-$13.18M
YoY Change	2.96%	5.96%	17.34%
Net Earnings / Revenue
Basic Earnings Per Share			-$4.56
Diluted Earnings Per Share	-$0.93	-$1.04	-$4.56
COMMON SHARES
Basic Shares Outstanding	3.169M shares	63.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.355M	$4.889M	$4.889M
YoY Change	-66.95%	-48.33%	-48.33%
Cash & Equivalents	$2.355M	$4.889M
Short-Term Investments
Other Short-Term Assets	$428.5K	$992.9K	$992.9K
YoY Change	-59.63%	-26.34%	-26.34%
Inventory	$2.735M	$2.645M	$2.645M
Prepaid Expenses	$428.5K	$992.9K
Receivables
Other Receivables
Total Short-Term Assets	$5.519M	$8.527M	$8.527M
YoY Change	-45.46%	-29.5%	-29.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$228.1K	$235.7K	$741.5K
YoY Change	13.25%	79.71%	-4.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$438.3K	$5.986K	$5.990K
YoY Change	7222.59%	0.0%	0.0%
Total Long-Term Assets	$1.136M	$747.5K	$747.5K
YoY Change	38.9%	-4.24%	-4.24%
TOTAL ASSETS
Total Short-Term Assets	$5.519M	$8.527M	$8.527M
Total Long-Term Assets	$1.136M	$747.5K	$747.5K
Total Assets	$6.655M	$9.274M	$9.274M
YoY Change	-39.15%	-27.97%	-27.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$524.0K	$614.0K	$614.0K
YoY Change	-37.16%	-22.39%	-22.39%
Accrued Expenses	$1.279M	$1.061M	$1.061M
YoY Change	144.09%	40.99%	40.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$28.48K	$28.48K	$28.48K
YoY Change
Total Short-Term Liabilities	$1.832M	$1.704M	$1.704M
YoY Change	34.89%	10.36%	10.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$324.1K	$365.9K	$365.9K
YoY Change	-32.71%	-29.38%	-29.38%
Total Long-Term Liabilities	$324.1K	$365.9K	$365.9K
YoY Change	-36.47%	-33.06%	-33.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.832M	$1.704M	$1.704M
Total Long-Term Liabilities	$324.1K	$365.9K	$365.9K
Total Liabilities	$2.156M	$2.070M	$2.070M
YoY Change	15.41%	-0.99%	-0.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$84.81M	-$81.87M
YoY Change	18.54%	19.19%
Common Stock	$317.00	$317.00
YoY Change	-92.88%	-92.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.499M	$7.205M	$7.205M
YoY Change
Total Liabilities & Shareholders Equity	$6.655M	$9.274M	$9.274M
YoY Change	-39.15%	-27.97%	-27.97%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.943M	-$3.290M	-$13.18M
YoY Change	2.96%	5.96%	17.34%
Depreciation, Depletion And Amortization	$34.52K	$32.13K	$96.66K
YoY Change	81.3%	51.13%	-16.84%
Cash From Operating Activities	-$2.507M	-$3.089M	-$12.77M
YoY Change	-19.1%	16.43%	14.81%
INVESTING ACTIVITIES
Capital Expenditures	$27.00K	$38.57K	$202.6K
YoY Change	-69.78%		350.17%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$27.00K	-$38.57K	-$202.6K
YoY Change	-69.78%		350.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$8.400M
YoY Change			-20.88%
Debt Paid & Issued, Net	$0.00
YoY Change
Cash From Financing Activities	$0.00	0.000	$8.400M
YoY Change	-100.0%	-100.0%	-37.32%
NET CHANGE
Cash From Operating Activities	-$2.507M	-3.089M	-$12.77M
Cash From Investing Activities	-$27.00K	-38.57K	-$202.6K
Cash From Financing Activities	$0.00	0.000	$8.400M
Net Change In Cash	-$2.534M	-3.127M	-$4.572M
YoY Change	8.55%	34.12%	-304.65%
FREE CASH FLOW
Cash From Operating Activities	-$2.507M	-$3.089M	-$12.77M
Capital Expenditures	$27.00K	$38.57K	$202.6K
Free Cash Flow	-$2.534M	-$3.127M	-$12.97M
YoY Change	-20.52%	17.89%	16.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89068015	usd
CY2022Q4	ndra	Stock Payable StockPayable	6073	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81869902	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	317	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1429150	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1075376	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5174215	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4940398	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	13157559	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	11498305	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13157559	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-11498305	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-308600	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21533	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-41545	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21533	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	267055	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001681682
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3169103	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2127725	shares
CY2023Q1	ndra	Shares Available For Issuance Increased Under The Omnibus Plan SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan	867966	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022	ndra	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37969
CY2022	dei	Entity Registrant Name EntityRegistrantName	ENDRA Life Sciences Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0579295
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3600 Green Court
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48105-1570
CY2022	dei	City Area Code CityAreaCode	734
CY2022	dei	Local Phone Number LocalPhoneNumber	335-0468
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	NDRA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5482531	usd
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	15628360	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3169103	shares
CY2022	dei	Auditor Firm AuditorFirmId	587
CY2022	dei	Auditor Name AuditorName	RBSM LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Cash Cash	4889098	usd
CY2021Q4	us-gaap	Cash Cash	9461534	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5986	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5986	usd
CY2022Q4	us-gaap	Assets Assets	9274147	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1523012	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1411437	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	152228	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	28484	usd
CY2021Q4	us-gaap	Loans Payable LoansPayable	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1703724	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	28484	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	518147	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	546631	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2090398	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3169103	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2127725	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9274147	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6554194	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13179092	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11231250	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13179092	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11231250	usd
CY2022	us-gaap	Dividends Dividends	0	usd
CY2021	us-gaap	Dividends Dividends	121071	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13179092	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11352321	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.56
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.55
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2891292	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2046135	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	7169322	usd
CY2021	ndra	Series A Convertible Preferred Stock Converted To Common Stock Amount SeriesAConvertiblePreferredStockConvertedToCommonStockAmount	0	usd
CY2021	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	10615975	usd
CY2021	ndra	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	2785627	usd
CY2021	ndra	Common Stock Issued For Option Exercise Amount CommonStockIssuedForOptionExerciseAmount	0	usd
CY2021	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	1334112	usd
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2021	ndra	Common Stock Issued For Services Amount CommonStockIssuedForServicesAmount	74000	usd
CY2021	ndra	Stock Issued For Rsu Amount StockIssuedForRsuAmount	36460	usd
CY2021	ndra	Deemed Dividend DeemedDividend	0	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-11231250	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10784246	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10784246	usd
CY2022	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	8399512	usd
CY2022	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	1199838	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13179092	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2022	us-gaap	Profit Loss ProfitLoss	13179092	usd
CY2021	us-gaap	Profit Loss ProfitLoss	11231250	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	96661	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	116238	usd
CY2022	ndra	Fixed Assets Write Off FixedAssetsWriteOff	1391	usd
CY2021	ndra	Fixed Assets Write Off FixedAssetsWriteOff	9874	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1199838	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1444572	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	137597	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	108177	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-308600	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-355128	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	957203	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1360139	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	694958	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	111575	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	491104	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-132330	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-100338	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12769371	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11122384	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	410358	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	392425	shares
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	202577	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-202577	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2785627	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8399512	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10615975	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8399512	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13401602	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4572436	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2234218	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9461534	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7227316	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4889098	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9461534	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	59113	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	57655	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Dividends Dividends	0	usd
CY2021	us-gaap	Dividends Dividends	121071	usd
CY2022	ndra	Conversion Of Series A Convertible Preferred Stock ConversionOfSeriesAConvertiblePreferredStock	0	usd
CY2021	ndra	Conversion Of Series A Convertible Preferred Stock ConversionOfSeriesAConvertiblePreferredStock	-7	usd
CY2022	ndra	Stock Dividend Payable StockDividendPayable	7790	usd
CY2021	ndra	Stock Dividend Payable StockDividendPayable	-3068	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	505816	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	643413	usd
CY2022	ndra	Lease Liability LeaseLiability	518147	usd
CY2021	ndra	Lease Liability LeaseLiability	650477	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic has prompted governments and regulatory bodies throughout the world to issue “stay-at-home” or similar orders, and enact restrictions on the performance of “non-essential” services, public gatherings and travel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it continues impact worldwide macroeconomic conditions, the emergence of variants of the virus and effectiveness of vaccines, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2022 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Despite the Company’s efforts, the ultimate impact of COVID-19 on the Company’s business depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.</p>
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	505816	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	643413	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	518147	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	650477	usd
CY2022	ndra	Research And Development Expense1 ResearchAndDevelopmentExpense1	6554194	usd
CY2021	ndra	Research And Development Expense1 ResearchAndDevelopmentExpense1	5482531	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	usd
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	158925	usd
CY2021Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	117133	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1523012	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1411437	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	410358	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	392425	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	On January 1, 2023, the pool of shares issuable under the Omnibus Plan automatically increased by 867,966 shares from 454,204 shares to 1,322,169 shares
CY2022Q4	us-gaap	Cumulative Dividends CumulativeDividends	81869902	usd
CY2022Q4	ndra	Working Capital WorkingCapital	6822966	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	262481	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.17
CY2022	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y5M1D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	141975	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.08
CY2022	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y18D
CY2022Q4	us-gaap	Inventory Net InventoryNet	2644717	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1284578	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	738720	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	605248	usd
CY2022Q4	us-gaap	Development In Process DevelopmentInProcess	140617	usd
CY2021Q4	us-gaap	Development In Process DevelopmentInProcess	107682	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	643682	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	581800	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235655	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131130	usd
CY2022	us-gaap	Depreciation Depreciation	96661	usd
CY2021	us-gaap	Depreciation Depreciation	116238	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	613961	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	791052	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	60638	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	101459	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	683738	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	396043	usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	308600	usd
CY2022Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	90000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	ndra	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	9889000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3169103	shares
CY2022Q4	ndra	Stock Payable Share StockPayableShare	6073	usd
CY2022	ndra	Total Common Stock Shares Issued TotalCommonStockSharesIssued	1041377	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8399512	usd
CY2021	ndra	Total Common Stock Shares Issued TotalCommonStockSharesIssued	425241	shares
CY2021	ndra	Shares In Return SharesInReturn	229348	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10615975	usd
CY2021	ndra	Common Stock Shares Upon Warrat Exercise Shares CommonStockSharesUponWarratExerciseShares	178395	shares
CY2021	ndra	Common Stock Shares Upon Warrant Exercise Amount CommonStockSharesUponWarrantExerciseAmount	2785627	usd
CY2021	ndra	Common Stock Shares Upon Cashless Warrant Exercise CommonStockSharesUponCashlessWarrantExercise	10145	usd
CY2021	ndra	Common Stock Shares Upon Cashless Option Exercise CommonStockSharesUponCashlessOptionExercise	1192	shares
CY2021	ndra	Shares For Services Value SharesForServicesValue	1626	usd
CY2021	ndra	Common Stock Services Valued CommonStockServicesValued	74000	usd
CY2021	ndra	Common Stock Shares Upon Vesting Of Restricted Units CommonStockSharesUponVestingOfRestrictedUnits	1141	usd
CY2021	ndra	Resticted Stock Units Valued RestictedStockUnitsValued	36460	usd
CY2022	ndra	Aggregate Fair Value Of Stock Options Granted AggregateFairValueOfStockOptionsGranted	919915	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	12554	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	391902	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.47
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	180742	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	41.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M8D
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	196721	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	202624	usd
CY2022Q4	ndra	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	202624	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	601969	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83822	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	518147	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	152228	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	365919	usd
CY2022	ndra	Rent Expenses RentExpenses	213912	usd
CY2021	ndra	Rent Expenses RentExpenses	178620	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17251804	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14200629	usd
CY2022Q4	ndra	Stock Based Compensation StockBasedCompensation	0	usd
CY2021Q4	ndra	Stock Based Compensation StockBasedCompensation	28720	usd
CY2022Q4	ndra	Fair Value Of Options FairValueOfOptions	311958	usd
CY2021Q4	ndra	Fair Value Of Options FairValueOfOptions	346869	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16939846	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13825040	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16939846	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13825040	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0580	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0580	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2680	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2680	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	65200000	usd
CY2022Q4	ndra	Net Operating Loss Carryforward Begain To Expire NetOperatingLossCarryforwardBegainToExpire	16000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001654954-23-003044-index-headers.html	Edgar Link	pending
0001654954-23-003044-index.html	Edgar Link	pending
0001654954-23-003044.txt	Edgar Link	pending
0001654954-23-003044-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ndra-20221231.xsd	Edgar Link	pending
ndra_10k.htm	Edgar Link	pending
ndra_10kimg5.jpg	Edgar Link	pending
ndra_10kimg6.jpg	Edgar Link	pending
ndra_ex106.htm	Edgar Link	pending
ndra_ex211.htm	Edgar Link	pending
ndra_ex231.htm	Edgar Link	pending
ndra_ex232.htm	Edgar Link	pending
ndra_ex311.htm	Edgar Link	pending
ndra_ex312.htm	Edgar Link	pending
ndra_ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
ndra-20221231_cal.xml	Edgar Link	unprocessable
ndra-20221231_def.xml	Edgar Link	unprocessable
ndra-20221231_lab.xml	Edgar Link	unprocessable
ndra-20221231_pre.xml	Edgar Link	unprocessable
ndra_10k_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NDRA
ENDRA Life Sciences Inc. Stock $ndra

2023 Q1 Form 10-K Financial Statement

#000165495423003044 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA ENDRA Life Sciences Inc. Stock $ndra

2023 Q1 Form 10-K Financial Statement

#000165495423003044 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA
ENDRA Life Sciences Inc. Stock $ndra